Literature DB >> 28985723

Correction to: Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study.

Sandra Wagner1,2, Marie Metzger1, Martin Flamant3, Pascal Houillier4,5, Jean-Philippe Haymann6, François Vrtovsnik3, Eric Thervet5,7, Jean-Jacques Boffa6, Ziad A Massy1,2,8, Bénédicte Stengel9,10, Patrick Rossignol2,11.   

Abstract

Entities:  

Year:  2017        PMID: 28985723      PMCID: PMC5629754          DOI: 10.1186/s12882-017-0723-2

Source DB:  PubMed          Journal:  BMC Nephrol        ISSN: 1471-2369            Impact factor:   2.388


× No keyword cloud information.
In the original version of this article [1], published on 12 September 2017, the explanation of a and b in the footnote of Table 2 were switched during typesetting. In this Correction Table 2, the incorrect and correct version of its footnote are shown. The affected part of the footnote is marked in italics. The original publication of this article has been corrected.
Table 2

Odds ratios of low or high plasma potassium associated with baseline patient characteristics – Multinomial logistic regression using patients with plasma potassium of 4–5 mmol/L as the reference group

Plasma potassium (mmol/L)
<4>5
Age (per year)0.99 (0.98–1.00)0.98 (0.96–0.99)
Women vs men1.49 (1.16–1.90)0.47 (0.30–0.72)
Sub-Saharan vs other ethnicity1.35 (0.99–1.83)1.15 (0.66–1.99)
mGFR (ml/min/1.73m2)
<150.11 (0.05–0.23)29.65 (10.87–80.88)
15–300.26 (0.18–0.38)13.58 (5.71–32.3)
30–450.47 (0.34–0.63)5.70 (2.42–13.45)
45–600.67 (0.49–0.90)2.70 (1.07–6.85)
>6011
BMI
<191.46 (0.83–2.59)1.49 (0.65–3.43)
19–2511
25–300.85 (0.66–1.10)0.78 (0.51–1.20)
>300.78 (0.57–1.07)1.05 (0.65–1.73)
Smoking status
Never smoked11
Former smoker0.85 (0.66–1.11)1.02 (0.67–1.54)
Active smoker0.76 (0.54–1.06)1.66 (1.03–2.67)
Mean blood pressure (per mmHg)1.01 (1.00–1.02)1.01 (0.99–1.02)
Cardio-vascular history0.63 (0.46–0.88)0.81 (0.51–1.28)
ACR (mg/mmol)
<311
3–301.07 (0.82–1.40)1.25 (0.76–2.08)
>300.80 (0.59–1.10)1.13 (0.67–1.90)
Diabetes0.86 (0.66–1.13)1.56 (1.04–2.34)
Urine potassium0.99 (0.99–1.00)1.01 (1.00–1.01)
Serum albumin
≥3511
<351.23 (0.87–1.74)1.23 (0.76–1.98)
Serum potassium increasing drugsa 0.58 (0.44–0.78)2.50 (1.17–5.35)
Serum potassium-lowering drugsb 1.70 (1.33–2.17)1.01 (0.69–1.49)

a loop or thiazide diuretic, kayexalate or bicarbonates b ACEi or ARBs or potassium-sparing diuretics

BMI body mass index, CVD cardiovascular disease, mGFR measured GFR, ACR, ratio of urinary albumin to creatinine

The analyses was adjusted for center

Table 2

Odds ratios of low or high plasma potassium associated with baseline patient characteristics – Multinomial logistic regression using patients with plasma potassium of 4–5 mmol/L as the reference group

Plasma potassium (mmol/L)
<4>5
Age (per year)0.99 (0.98–1.00)0.98 (0.96–0.99)
Women vs men1.49 (1.16–1.90)0.47 (0.30–0.72)
Sub-Saharan vs other ethnicity1.35 (0.99–1.83)1.15 (0.66–1.99)
mGFR (ml/min/1.73m2)
<150.11 (0.05–0.23)29.65 (10.87–80.88)
15–300.26 (0.18–0.38)13.58 (5.71–32.3)
30–450.47 (0.34–0.63)5.70 (2.42–13.45)
45–600.67 (0.49–0.90)2.70 (1.07–6.85)
>6011
BMI
<191.46 (0.83–2.59)1.49 (0.65–3.43)
19–2511
25–300.85 (0.66–1.10)0.78 (0.51–1.20)
>300.78 (0.57–1.07)1.05 (0.65–1.73)
Smoking status
Never smoked11
Former smoker0.85 (0.66–1.11)1.02 (0.67–1.54)
Active smoker0.76 (0.54–1.06)1.66 (1.03–2.67)
Mean blood pressure (per mmHg)1.01 (1.00–1.02)1.01 (0.99–1.02)
Cardio-vascular history0.63 (0.46–0.88)0.81 (0.51–1.28)
ACR (mg/mmol)
<311
3–301.07 (0.82–1.40)1.25 (0.76–2.08)
>300.80 (0.59–1.10)1.13 (0.67–1.90)
Diabetes0.86 (0.66–1.13)1.56 (1.04–2.34)
Urine potassium0.99 (0.99–1.00)1.01 (1.00–1.01)
Serum albumin
≥3511
<351.23 (0.87–1.74)1.23 (0.76–1.98)
Serum potassium increasing drugsa 0.58 (0.44–0.78)2.50 (1.17–5.35)
Serum potassium-lowering drugsb 1.70 (1.33–2.17)1.01 (0.69–1.49)

a ACEi or ARBs or potassium-sparing diuretics b loop or thiazide diuretic, kayexalate or bicarbonates

BMI, body mass index, CVD, cardiovascular disease, mGFR, measured GFR, ACR, ratio of urinary albumin to creatinine

The analyses was adjusted for center

Odds ratios of low or high plasma potassium associated with baseline patient characteristics – Multinomial logistic regression using patients with plasma potassium of 4–5 mmol/L as the reference group a loop or thiazide diuretic, kayexalate or bicarbonates b ACEi or ARBs or potassium-sparing diuretics BMI body mass index, CVD cardiovascular disease, mGFR measured GFR, ACR, ratio of urinary albumin to creatinine The analyses was adjusted for center Odds ratios of low or high plasma potassium associated with baseline patient characteristics – Multinomial logistic regression using patients with plasma potassium of 4–5 mmol/L as the reference group a ACEi or ARBs or potassium-sparing diuretics b loop or thiazide diuretic, kayexalate or bicarbonates BMI, body mass index, CVD, cardiovascular disease, mGFR, measured GFR, ACR, ratio of urinary albumin to creatinine The analyses was adjusted for center Originally Table 2 and its footnote were published as followed: The analyses was adjusted for center The correct version of Table 2 and its footnote is: The analyses was adjusted for center
  1 in total

1.  Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study.

Authors:  Sandra Wagner; Marie Metzger; Martin Flamant; Pascal Houillier; Jean-Philippe Haymann; François Vrtovsnik; Eric Thervet; Jean-Jacques Boffa; Ziad A Massy; Bénédicte Stengel; Patrick Rossignol
Journal:  BMC Nephrol       Date:  2017-09-12       Impact factor: 2.388

  1 in total
  1 in total

1.  A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology.

Authors:  Patrick Rossignol
Journal:  Eur Heart J Suppl       Date:  2019-02-26       Impact factor: 1.803

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.